文献速递腹部技术与安全MRPET

整合PET/MRI评估胰腺导管腺癌的早期治疗反应

Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI.
PubMed 文献 · AJR Am J Roentgenol · 2018-07-31

研究纳入13例晚期胰腺导管腺癌患者,在治疗前及治疗开始后4周行整合FDG PET/MRI,根据治疗开始后8-12周CT的RECIST 1.1标准分为应答者与非应答者。应答者原发胰腺肿瘤的MTV(p=0.003)和TLG(p=0.006)下降更显著,平均ADC(p=0.004)和最小ADC(p=0.024)升高更显著;4周时肿瘤大小变化两组无显著差异(p=0.11)。以MTV下降60%或TLG下降65%为阈值,PET应答者PFS(p=0.0004)和OS(p=0.013)更长;以平均或最小ADC升高20%为阈值,MRI应答者PFS(p=0.0002)和OS(p=0.027)更长。整合PET/MRI可提供晚期PDAC的早期治疗反应评估,从而可能允许对非应答者早期调整治疗。

要点

  • 治疗4周时MTV和TLG下降幅度在RECIST应答者中显著大于非应答者。
  • 治疗4周时平均ADC和最小ADC升高幅度在应答者中显著大于非应答者。
  • 治疗4周时肿瘤大小变化在应答者与非应答者间无显著差异(p=0.11)。

核心结论

  • 整合PET/MRI可提供晚期PDAC的早期治疗反应评估,从而可能允许对非应答者早期调整治疗。

研究设计与样本

  • 研究纳入13例晚期PDAC患者,在治疗前及治疗开始后4周行整合FDG PET/MRI,根据治疗开始后8-12周CT的RECIST 1.1标准分为应答者与非应答者。

诊断标准与关键数值

  • 以MTV下降60%或TLG下降65%为阈值,PET应答者较非应答者PFS更长(p=0.0004)、OS更长(p=0.013)。
  • 以平均或最小ADC升高20%为阈值,MRI应答者较非应答者PFS更长(p=0.0002)、OS更长(p=0.027)。
  • 治疗4周时MTV下降幅度应答者显著大于非应答者(p=0.003)。
  • 治疗4周时TLG下降幅度应答者显著大于非应答者(p=0.006)。
  • 治疗4周时平均ADC升高幅度应答者显著大于非应答者(p=0.004),最小ADC升高幅度应答者显著大于非应答者(p=0.024)。

临床应用与阅片要点

  • 治疗4周时肿瘤大小变化在应答者与非应答者间无显著差异(p=0.11)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The purpose of this study is to investigate early changes in 18F-FDG PET/MRI metrics after treatment in patients with advanced pancreatic ductal adenocarcinoma (PDAC) and to correlate those changes with eventual tumor response at standard-of-care CT.

SUBJECTS AND METHODS: Thirteen patients with advanced PDAC underwent integrated FDG PET/MRI before and 4 weeks after treatment initiation. Patients were classified as responders or nonresponders according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 at subsequent CT performed 8-12 weeks after treatment initiation. Changes in the primary tumor's maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) determined at PET and apparent diffusion coefficient (ADC) determined at DWI at 4 weeks were compared between responders and nonresponders.

RESULTS: Seven patients had a partial response according to RECIST, and six did not. Responders displayed significantly greater decreases in MTV (p = 0.003) and TLG (p = 0.006) in the primary pancreatic tumor at 4 weeks. Responders also displayed a greater increase in the mean (p = 0.004) and minimum (p = 0.024) ADC of the primary tumors. Tumor size change at 4 weeks was not significantly different between responders and nonresponders (p = 0.11). PET responders enjoyed longer progression-free survival (PFS) (p = 0.0004) and overall survival (OS) (p = 0.013) than did nonresponders, using either a 60% reduction in MTV or 65% reduction in TLG as a threshold. MRI responders had significantly longer PFS (p = 0.0002) and OS (p = 0.027) than did nonresponders, using a 20% increase in either mean or minimum ADC as a threshold.

CONCLUSION: Integrated PET/MRI can provide early response assessment in patients with advanced PDAC, thus potentially allowing early treatment adaptation in nonresponders.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Wang ZJ, Behr S, Consunji MV, et al. Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI. AJR Am J Roentgenol. 2018. PMID: 30063366. doi:10.2214/AJR.18.19602

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。